Viewpoint

Entire output for the 106 pathway signature in improvers from gene set enrichment analysis (GSEA). (PDF 367 kb

Additional file 3: of Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

List of 651 intrinsic genes used to cluster nilotinib samples in Fig.  2 . Gene symbols are color-coded based on their association with inflammatory (purple), normal-like (green) or fibroproliferative (red) intrinsic subsets. (XLSX 32 kb

Additional file 2: Table S2. of Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis

Gene lists used in these analyses. (XLSX 17 kb

Additional file 5: Table S4. of Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis

Processing body and stress granule proteins identified in this analysis. *Proteins with multiple subunits. Data indicate non-redundant peptide hits. (ODS 20 kb

Additional file 3: Table S3. of Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis

Systemic sclerosis (SSc)-specific enrichment of processes and components. Proteins differentially detected in SSc were analyzed using gProfiler. Statistically significant processes and components are shown. A) Peptides detected at any level across all four groups. B) Peptides identified in all SSc groups, but absent in controls. C) Analysis of 137 proteins differentially detected in SSc. BP biological process, CC cellular component, MF molecular function, ke KEGG pathway, re REACTOME pathway. (ODS 70 kb